Effect of a dietary supplement purposes in patients with osteoarthritis - Randomized, placebo-controlled, double-blind intervention study

Effect of a dietary supplement purposes in patients with osteoarthritis - Randomized, placebo-controlled, double-blind intervention study - Osteoarthritis study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000724

Enrollment

200

Registered

2011-06-01

Start date

2011-10-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M17.0

Interventions

Group 1: Verum: 2x2 capsules per day, nutrient supplements with ingredients glucosamine, chondroitin sulfate, hyaluronic acid, vitamin C, vitamin D and selenium Group 2: Placebo: 2x2 placebo capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women >18 years - diagnosed gonarthrosis - WOMAC subscore pain >/=15 points, >/=150 mm, respectively

Exclusion criteria

Exclusion criteria: allergy or intolerance to any component of the test product - severe chronic diseases (tumors etc) - severe cardiovascular disease, renal failure, liver disease - chronic inflammatory joint diseases, infectious diseases of the joints - classification of Kellgren stage IV - BMI >40 kg/m² - chronic diseases of the gastrointestinal tract - taking additional glucosamine, chondroitin and hyaluronic acid-containing products before or during the study - intra-articular injections - intra-articular and systemic corticosteroid therapy - pain relief or ointments during the study - pregnancy and lactation - alcohol, drug addiction - incapacitated subjects - refusal or withdrawal of consent by the subjects - simultaneous participation in another clinical study or participation within the past 30 days

Design outcomes

Primary

Measure	Time frame
WOMAC Score (Questionnaire), Measurement of changes after 24 weeks compared to baseline	—

Secondary

Measure	Time frame
generel health (questionnaire): at baseline and after 6, 12, 18 and 24 weeks - blood parameters (blood count, liver enzymes, glucose, HbA1c, blood lipids, hsCRP, vitamin C, vitamin D, selenium, glutathione peroxidase) (blood samples): at baseline and after 6, 12, 18 and 24 weeks- documentation of acute medication (questionnaire and diary): at baseline and after 6, 12, 18 and 24 weeks	—

Countries

Germany

Contacts

Public ContactInga Schneider

Leibniz Universität Hannover Institut für Lebensmittelwissenschaft und Humanernährung

schneider@nutrition.uni-hannover.de0511 762 5969

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026